Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
OtherClinical Investigations (Human)

Using, 68Ga-PSMA-11 PET/CT for therapy response assessment in patients with metastatic castration-resistant prostate cancer: an application of EAU/EANM recommendations in clinical practice.

Chloé S Denis, François Cousin, Bram De Laere, Roland Hustinx, Brieuc R Sautois and Nadia Withofs
Journal of Nuclear Medicine April 2022, jnumed.121.263611; DOI: https://doi.org/10.2967/jnumed.121.263611
Chloé S Denis
1 University Hospital of Liege, Belgium;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Chloé S Denis
François Cousin
1 University Hospital of Liege, Belgium;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for François Cousin
Bram De Laere
2 Ghent University, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Bram De Laere
Roland Hustinx
1 University Hospital of Liege, Belgium;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Roland Hustinx
Brieuc R Sautois
1 University Hospital of Liege, Belgium;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Brieuc R Sautois
Nadia Withofs
1 University Hospital of Liege, Belgium;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nadia Withofs
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

jnumed.121.263611
DOI 
https://doi.org/10.2967/jnumed.121.263611
PubMed 
35450960

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online April 21, 2022.

Article Versions

  • You are currently viewing a previous version of this article (April 21, 2022 - 12:52).
  • latest version (May 12, 2022 - 12:01).
  • View the most recent version of this article
Copyright & Usage 
Copyright © 2022 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Author Information

  1. Chlo&eacute S Denis1,
  2. Fran&ccedilois Cousin1,
  3. Bram De Laere2,
  4. Roland Hustinx1,
  5. Brieuc R Sautois1 and
  6. Nadia Withofs1
  1. 1 University Hospital of Liege, Belgium;
  2. 2 Ghent University, Belgium
  1. For correspondence or reprints contact: Chloé S. Denis, University Hospital of Liege, Avenue de L'Hopital 1, LIEGE 4000, Belgium. E-mail: chloe.denis@chuliege.be

Statistics from Altmetric.com

Cited By...

  • 16 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors
    Qaid Ahmed Shagera, Ioannis Karfis, Paulus Kristanto, Sideris Spyridon, Romain Diamand, Albert Santapau, Alexandre Peltier, Thierry Roumeguère, Patrick Flamen, Carlos Artigas
    Journal of Nuclear Medicine 2023 64 12
  • How to Report PSMA PET
    Mina Swiha, Narjess Ayati, Daniela E. Oprea-Lager, Francesco Ceci, Louise Emmett
    Seminars in Nuclear Medicine 2024 54 1
  • Advancements in PSMA ligand radiolabeling for diagnosis and treatment of prostate cancer: a systematic review
    Yuanzhuo Yan, Huixian Zhuo, Tengfei Li, Jintao Zhang, Min Tan, Yue Chen
    Frontiers in Oncology 2024 14
  • Heterogeneity of [68Ga]Ga-PSMA-11 PET/CT in metastatic castration-resistant prostate cancer: genomic characteristics and association with abiraterone response
    Jian Pan, Jinou Zhao, Xudong Ni, Bin Zhu, Xiaoxin Hu, Qifeng Wang, Yu Wei, Tingwei Zhang, Hualei Gan, Beihe Wang, Junlong Wu, Shaoli Song, Chang Liu, Dingwei Ye, Yao Zhu
    European Journal of Nuclear Medicine and Molecular Imaging 2023 50 6
  • Impact of PSMA PET on Prostate Cancer Management
    Adam B. Weiner, Raag Agrawal, Luca F. Valle, Ida Sonni, Amar U. Kishan, Matthew B. Rettig, Steven S. Raman, Jeremie Calais, Paul C. Boutros, Robert E. Reiter
    Current Treatment Options in Oncology 2024 25 2
  • Evaluating response to radium-223 using 68Ga-PSMA PET/CT imaging in patients with metastatic castration-resistant prostate cancer
    Qaid Ahmed Shagera, Thierry Gil, Elisa Barraco, Petra Boegner, Paulus Kristanto, Ziad El Ali, Spyridon Sideris, Nieves Martinez Chanza, Thierry Roumeguère, Patrick Flamen, Carlos Artigas
    Annals of Nuclear Medicine 2025 39 2
  • Prognostic Role of PSMA-Targeted Imaging in Metastatic Castration-Resistant Prostate Cancer: An Overview
    Matteo Caracciolo, Angelo Castello, Massimo Castellani, Mirco Bartolomei, Egesta Lopci
    Biomedicines 2024 12 10
  • PSMA PET/CT for treatment response evaluation at predefined time points is superior to PSA response for predicting survival in metastatic castration-resistant prostate cancer patients
    F. Kleiburg, L.F. de Geus-Oei, S.A.C. Luelmo, R. Spijkerman, J.J. Goeman, F.A.J. Toonen, F. Smit, T. van der Hulle, L. Heijmen
    European Journal of Radiology 2024 181
  • Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) of prostate cancer: current and emerging applications
    Shamus Moran, Heather H. Cheng, Emily Weg, Eric H. Kim, Delphine L. Chen, Amir Iravani, Joseph E. Ippolito
    Abdominal Radiology 2024 49 4
  • Should new organ involvement be included in Response Evaluation Criteria in PSMA Imaging?
    İhsan Kaplan, Halil Kömek, Canan Can, Nadiye Akdeniz, Yunus Güzel, Ferat Kepenek, Ayhan Şenol, Serdar İleri, Hüseyin Karaoğlan, İhsan Solmaz, Mehmet Serdar Yıldırım, Veysi Şenses, Fulya Kaya, Cihan Gündoğan
    Annals of Nuclear Medicine 2024 38 10

Article usage

Article usage: April 2022 to April 2025

AbstractFullPdf
Apr 20221571063
May 20221673069
Jun 2022486032
Jul 2022331013
Aug 2022242019
Sep 2022222022
Oct 202218309
Nov 2022143036
Dec 202213798181
Jan 20237994947
Feb 2023613921
Mar 20235371639
Apr 20233791717
May 20233231029
Jun 20237616233
Jul 20232716865
Aug 20233729235
Sep 20233326925
Oct 20232213626
Nov 20232713918
Dec 20232472156
Jan 202429173206
Feb 20242920325
Mar 20241317143
Apr 2024458732
May 2024126526
Jun 2024488124
Jul 202412913931
Aug 2024114117212
Sep 202420701301
Oct 20242645225
Nov 2024175719
Dec 2024124125
Jan 202585928
Feb 2025198925
Mar 2025199129
Apr 20251811838
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 66 (6)
Journal of Nuclear Medicine
Vol. 66, Issue 6
June 1, 2025
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Using, 68Ga-PSMA-11 PET/CT for therapy response assessment in patients with metastatic castration-resistant prostate cancer: an application of EAU/EANM recommendations in clinical practice.
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Using, 68Ga-PSMA-11 PET/CT for therapy response assessment in patients with metastatic castration-resistant prostate cancer: an application of EAU/EANM recommendations in clinical practice.
Chlo&eacute S Denis, Fran&ccedilois Cousin, Bram De Laere, Roland Hustinx, Brieuc R Sautois, Nadia Withofs
Journal of Nuclear Medicine Apr 2022, jnumed.121.263611; DOI: 10.2967/jnumed.121.263611

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Using, 68Ga-PSMA-11 PET/CT for therapy response assessment in patients with metastatic castration-resistant prostate cancer: an application of EAU/EANM recommendations in clinical practice.
Chlo&eacute S Denis, Fran&ccedilois Cousin, Bram De Laere, Roland Hustinx, Brieuc R Sautois, Nadia Withofs
Journal of Nuclear Medicine Apr 2022, jnumed.121.263611; DOI: 10.2967/jnumed.121.263611
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors
  • Google Scholar

More in this TOC Section

Clinical Investigations (Human)

  • The added value of 18F-FDG PET/CT compared to 68Ga-PSMA PET/CT in patients with castration-resistant prostate cancer
Show more Clinical Investigations (Human)

Clinical (Oncology: GU)

  • Pretherapeutic Comparative Dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer
  • A Comparison of 18F-DCFPyL, 18F-NaF, and 18F-FDG PET/CT in a Prospective Cohort of Men with Metastatic Prostate Cancer
  • Detection of Additional Primary Neoplasms on 18F-Fluciclovine PET/CT in Patients with Primary Prostate Cancer
Show more Clinical (Oncology: GU)

Similar Articles

Keywords

  • Oncology: GU
  • PET/CT
  • flare
  • PSMA PET/CT
  • prostate cancer
  • tumor quantification
  • mCRPC
SNMMI

© 2025 SNMMI

Powered by HighWire